Compare Stocks: PBLS, BBIO, SMMT, and BMRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$67.13 +3.4%	$73.11	$52.75 ▼ $93.42	$12.69B	0.97	2.97 million shs	2.64 million shs
BMRN BioMarin Pharmaceutical	$56.05 +1.7%	$63.19	$49.26 ▼ $70.98	$10.67B	0.22	2.29 million shs	2.92 million shs
PBLS Parabilis Medicines	$25.18 -2.7%	$35.44	$24.51 ▼ $42.49	$3.20B	N/A	1.40 million shs	954,611 shs
SMMT Summit Therapeutics	$15.37 +1.6%	$15.74	$12.07 ▼ $29.23	$12.10B	-1.51	7.47 million shs	4.73 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+2.59%	-2.35%	-10.28%	-19.13%	+14.94%
BMRN BioMarin Pharmaceutical	+1.40%	-0.11%	-16.97%	-8.10%	+5.09%
PBLS Parabilis Medicines	-3.58%	-10.17%	-28.40%	-10.91%	+2,588,999,900.00%
SMMT Summit Therapeutics	-2.51%	-15.71%	-17.86%	+9.96%	-30.44%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$67.13 +3.4%	$73.11	$52.75 ▼ $93.42	$12.69B	0.97	2.97 million shs	2.64 million shs
BMRN BioMarin Pharmaceutical	$56.05 +1.7%	$63.19	$49.26 ▼ $70.98	$10.67B	0.22	2.29 million shs	2.92 million shs
PBLS Parabilis Medicines	$25.18 -2.7%	$35.44	$24.51 ▼ $42.49	$3.20B	N/A	1.40 million shs	954,611 shs
SMMT Summit Therapeutics	$15.37 +1.6%	$15.74	$12.07 ▼ $29.23	$12.10B	-1.51	7.47 million shs	4.73 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+2.59%	-2.35%	-10.28%	-19.13%	+14.94%
BMRN BioMarin Pharmaceutical	+1.40%	-0.11%	-16.97%	-8.10%	+5.09%
PBLS Parabilis Medicines	-3.58%	-10.17%	-28.40%	-10.91%	+2,588,999,900.00%
SMMT Summit Therapeutics	-2.51%	-15.71%	-17.86%	+9.96%	-30.44%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.83	Moderate Buy	$104.75	56.04% Upside
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$88.87	58.55% Upside
PBLS Parabilis Medicines	2.71	Moderate Buy	$41.67	65.48% Upside
SMMT Summit Therapeutics	2.58	Moderate Buy	$28.61	86.13% Upside

Current Analyst Ratings Breakdown

Latest PBLS, BBIO, SMMT, and BMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/15/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$82.00 ➝ $92.00
10/15/2026	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$114.00 ➝ $88.00
10/14/2026	BMRN BioMarin Pharmaceutical	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$111.00 ➝ $114.00
10/12/2026	BMRN BioMarin Pharmaceutical	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Outperform ➝ Strong-Buy	$109.00
10/7/2026	BBIO BridgeBio Pharma	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$157.00 ➝ $156.00
10/6/2026	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	BBIO BridgeBio Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	BBIO BridgeBio Pharma	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	SMMT Summit Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Perform
10/5/2026	BBIO BridgeBio Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$502.08M	26.14	N/A	N/A	($10.77) per share	-6.23
BMRN BioMarin Pharmaceutical	$3.22B	3.37	$2.90 per share	19.33	$31.68 per share	1.77
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$724.93M	-$3.57	N/A	N/A	N/A	-97.03%	N/A	-61.19%	10/28/2026 (Estimated)
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	32.82	10.34	0.38	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
PBLS Parabilis Medicines	-$145.89M	-$2.13	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest PBLS, BBIO, SMMT, and BMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/28/2026	Q3 2026	BBIO BridgeBio Pharma	-$0.5633	N/A	N/A	N/A	$281.65 million	N/A
10/26/2026	Q3 2026	BMRN BioMarin Pharmaceutical	$1.35	N/A	N/A	N/A	$1.02 billion	N/A
10/19/2026	Q3 2026	SMMT Summit Therapeutics	-$0.2806	N/A	N/A	N/A	$0.07 million	N/A
8/13/2026	Q2 2026	PBLS Parabilis Medicines	-$0.16	-$2.32	-$2.16	-$2.32	N/A	$0.15 million
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	1.23	1.17
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
PBLS Parabilis Medicines	N/A	17.91	17.91
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BMRN BioMarin Pharmaceutical	98.71%
PBLS Parabilis Medicines	N/A
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	14.23%
BMRN BioMarin Pharmaceutical	0.68%
PBLS Parabilis Medicines	N/A
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	839	195.49 million	167.67 million	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
PBLS Parabilis Medicines	145	123.53 million	N/A	N/A
SMMT Summit Therapeutics	265	799.73 million	131.96 million	Optionable

PBLS, BBIO, SMMT, and BMRN Headlines

Recent News About These Companies

Summit Therapeutics Sees Unusually Large Options Volume (NASDAQ:SMMT)

October 13 at 3:39 PM | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Shares Down 5.8% - Here's What Happened

October 13 at 12:19 PM | marketbeat.com

Summit Therapeutics (SMMT) Projected to Release Earnings on Monday

October 12 at 1:26 AM | americanbankingnews.com

Summit Therapeutics (SMMT) Set to Release Quarterly Earnings on Monday

October 12 at 1:25 AM | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Stock Jumps 3.6% - What's Next?

October 7, 2026 | marketbeat.com

SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos

October 5, 2026 | zacks.com

Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration

October 2, 2026 | finance.yahoo.com

Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab

October 2, 2026 | rttnews.com

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

October 2, 2026 | businesswire.com

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

October 2, 2026 | businesswire.com

What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership?

October 1, 2026 | finance.yahoo.com

AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets

September 30, 2026 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Argenx Se (ARGX) and Obsidian Therapeutics (OBX)

September 30, 2026 | theglobeandmail.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 7.1% - What's Next?

September 30, 2026 | marketbeat.com

AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets

September 30, 2026 | 247wallst.com

AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says

September 30, 2026 | finance.yahoo.com

Summit Therapeutics PLC ADR (SMMT)

September 30, 2026 | ca.investing.com

Summit Shares Jump on $2B Strategic Investment From AstraZeneca

September 29, 2026 | zacks.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Still a Buy?

September 29, 2026 | marketbeat.com

Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals

September 29, 2026 | invezz.comI

AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal

September 29, 2026 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBLS, BBIO, SMMT, and BMRN Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$67.13 +2.19 (+3.37%)

Closing price 04:00 PM Eastern

Extended Trading

$67.12 -0.01 (-0.01%)

As of 07:52 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BioMarin Pharmaceutical NASDAQ:BMRN

$56.05 +0.91 (+1.65%)

Closing price 04:00 PM Eastern

Extended Trading

$56.68 +0.63 (+1.12%)

As of 07:30 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Parabilis Medicines NASDAQ:PBLS

$25.18 -0.71 (-2.74%)

As of 04:00 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

Summit Therapeutics NASDAQ:SMMT

$15.37 +0.24 (+1.59%)

Closing price 04:00 PM Eastern

Extended Trading

$15.42 +0.05 (+0.35%)

As of 07:52 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBLS, BBIO, SMMT, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBLS, BBIO, SMMT, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBLS, BBIO, SMMT, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBLS, BBIO, SMMT, and BMRN Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

BioMarin Pharmaceutical NASDAQ:BMRN

Parabilis Medicines NASDAQ:PBLS

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBLS, BBIO, SMMT, and BMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBLS, BBIO, SMMT, and BMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBLS, BBIO, SMMT, and BMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBLS, BBIO, SMMT, and BMRN Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

BioMarin Pharmaceutical NASDAQ:BMRN

Parabilis Medicines NASDAQ:PBLS

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools